ANS-6637 is under clinical development by Amygdala Neurosciences and currently in Phase I for Substance (Drug) Abuse. According to GlobalData, Phase I drugs for Substance (Drug) Abuse have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ANS-6637’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANS-6637 (GS-6637) is under development for the treatment of cocaine, opiate craving and binge eating disorder. It is formulated as a tablet and administered through the oral route. The drug candidate acts by targetting acetaldehyde dehydrogenase-2 (ALDH2) inhibitor. It was also under development for the treatment of alcohol addiction, smoking cessation.
Amygdala Neurosciences overview
Amygdala Neurosciences is a biopharmaceutical company. The company develops novel therapeutics for the treatment of opioid, nicotine, alcohol and cocaine use disorders. Amygdala Neurosciences is headquartered in Palo Alto, California, the US.
For a complete picture of ANS-6637’s drug-specific PTSR and LoA scores, buy the report here.